A novel pathogenetic mutation in clonal eosinophilia.
Tefferi
Ayalew
A
D001549:Benzamides; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1; D002894:Chromosomes, Human, Pair 4; D002999:Clone Cells / Q000473:pathology; D004252:DNA Mutational Analysis; D004802:Eosinophilia / Q000188:drug therapy / Q000209:etiology / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D020128:Inhibitory Concentration 50; D009154:Mutation; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D012074:Remission Induction; D014178:Translocation, Genetic; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha